Tilray Brands, Inc. (TLRY)
Nasdaq: TLRY · Medicinal Chemicals & Botanical Products · New York, NY · filing with the SEC since 2018
Who owns Tilray Brands, Inc.
As filed with the SECHolders of 5% or more
0
No Schedule 13D or 13G naming this company is on file.
Directors and officers
10
report now, of 25 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 0 named at left.
Holders of 5% or moreshare of the class, as filed
No holder of 5% or more is on file in a Schedule 13D or 13G naming this company.
What TLRY reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Aphria Diamond
An entity · consolidated entity · owns, named in the 10-K filed Jul 28, 2026
CC Pharma Nordic ApS
An entity · consolidated entity · owns, named in the 10-K filed Jul 28, 2026
ColCanna S.A.S.
An entity · consolidated entity · owns, named in the 10-K filed Jul 28, 2026
Superhero Acquisition LP
An entity · consolidated entity · owns, named in the 10-K filed Jul 28, 2026
Acquisition of Montauk Brewing Company, Inc.
A company bought · acquisition · owns, named in the 10-K filed Jul 28, 2026
HEXO Acquisition
A company bought · acquisition · owns, named in the 10-K filed Jul 28, 2026
Lyphe Group
A company bought · acquisition · owns, named in the 10-K filed Jul 28, 2026
144 subsidiaries in 15 countries, from the list filed with the 10-K filed Jul 28, 2026.
Insider tradesForm 4
1sales
3purchases
0sales on a scheduled plan
1people selling
$200,000sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 26 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Hopkinson David G. | director | 1 | $200,000 | 0 | 0 | $0 |
| Merton Carl A | Chief Financial Officer | 0 | $0 | 0 | 1 | $0 |
| Faltischek Denise M | Chief Strategy Officer | 0 | $0 | 0 | 1 | $0 |
| Gendel Mitchell | Global General Counsel | 0 | $0 | 0 | 1 | $0 |